2/16/2010 - First Treatment to Improve Survival in 20 Years Now Available for Patients with Osteosarcoma (Bone Cancer)

Osaka, Japan and London, UK, February 1 - Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Pharmaceuticals Europe Limited ("TPEU"), its wholly owned subsidiary for oversight of pan-European sales and marketing, jointly announced today that Mepact(R) (mifamurtide)(1), the first new treatment in 20 years to improve survival in patients with osteosarcoma (malignant bone cancer)(2), is now commercially available in the European Union - via a paid named-patient programme in countries where it is not initially reimbursed.

Osteosarcoma is a rare and often fatal disease, with approximately 1,200 new cases diagnosed in Europe each year; primarily children and young adults(3). The standard treatment for osteosarcoma is surgical removal of the tumour (resection) with combination chemotherapy before and after surgery. Mepact is used in combination with these other anticancer medicines after the cancer has been removed by surgery(1).

Data from the largest independent clinical study ever completed in osteosarcoma (662 patients) conducted by the Children's Oncology Group in the USA, showed that when combined with chemotherapy, Mepact reduced the risk of death by almost one third compared with chemotherapy alone. In addition, 78 percent of patients survived after six years of follow-up after treatment with Mepact and chemotherapy, compared with 70 percent receiving chemotherapy alone(4).

"There has been a significant lack of progress during the last two decades in treating osteosarcoma," said Ian Lewis, Professor of Cancer Studies at St. James University Hospital in Leeds, England. "The availability of mifamurtide brings hope to children and young adults in need of a more positive treatment option for this devastating disease."

Dr Erich Brunn, Chief Executive Officer for TPEU said, "This is an important milestone for Takeda in Europe and for the treatment of osteosarcoma. We are excited to bring this innovation to patients and physicians".

Takeda anticipates that final reimbursement decisions in European countries will be completed during the course of 2010.

About mifamurtide

Mifamurtide works by activating the body's immune system to kill microscopic fragments of tumour cells (micro-metastases) which can break away from the main site of the osteosarcoma in the bone. These fragments can be carried in the blood to other parts of the body, particularly the lungs, allowing the disease to develop further. Disease progression in the lungs is in fact, the primary cause of death in osteosarcoma(5).

Mifamurtide is indicated for the treatment of high-grade, resectable, non-metastatic osteosarcoma after complete surgical removal of the tumour (resection) in children, adolescents and young adults ('High grade' means that the cancer is a severe type, and 'non metastatic' means that it is at an early stage and has not spread. It is administered by intravenous injection over the course of one hour, twice a week for 12 weeks, and then once a week for 24 additional weeks, for a total of 36 weeks of therapy or 48 doses(3).

Safety Information

Clinical experience with mifamurtide suggests that the most common side effects are fever and chills, which can be prevented or reduced with simple premedication such as paracetemol(6). Detailed recommendations for the use of mifamurtide are described in the Summary of Product Characteristics (SPC) which is published in the European Public Assessment Report (EPAR) and is available in all official European Union languages.

Regulatory Progress

In June 2009 Takeda acquired IDM Pharma, Inc., which had already obtained Market Authorization Approval for Mepact in the European Union in March 2009(3), and now, TPEU is responsible for its commercialization in Europe. Millennium: The Takeda Oncology Company (Cambridge, Mass.) is responsible for the global oncology strategy of the Takeda Group and for the development of Mepact.